- Home
- CRIS vs COEP Comparison
CRIS vs COEP Comparison
Compare CRIS & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- COEP
- Stock Information
- Founded
- CRIS 2000
- COEP 2017
- Country
- CRIS United States
- COEP United States
- Employees
- CRIS N/A
- COEP N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRIS Health Care
- COEP Health Care
- Exchange
- CRIS Nasdaq
- COEP Nasdaq
- Market Cap
- CRIS 21.3M
- COEP 27.4M
- IPO Year
- CRIS 2000
- COEP N/A
- Fundamental
- Price
- CRIS $1.80
- COEP $9.81
- Analyst Decision
- CRIS Strong Buy
- COEP
- Analyst Count
- CRIS 2
- COEP 0
- Target Price
- CRIS $16.50
- COEP N/A
- AVG Volume (30 Days)
- CRIS 179.9K
- COEP 37.8K
- Earning Date
- CRIS 07-31-2025
- COEP 08-15-2025
- Dividend Yield
- CRIS N/A
- COEP N/A
- EPS Growth
- CRIS N/A
- COEP N/A
- EPS
- CRIS N/A
- COEP N/A
- Revenue
- CRIS $11,202,000.00
- COEP $62,874.00
- Revenue This Year
- CRIS N/A
- COEP N/A
- Revenue Next Year
- CRIS $10.67
- COEP N/A
- P/E Ratio
- CRIS N/A
- COEP N/A
- Revenue Growth
- CRIS 14.17
- COEP N/A
- 52 Week Low
- CRIS $1.02
- COEP $2.31
- 52 Week High
- CRIS $8.29
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- CRIS 42.69
- COEP 65.80
- Support Level
- CRIS $1.70
- COEP $7.25
- Resistance Level
- CRIS $2.01
- COEP $9.90
- Average True Range (ATR)
- CRIS 0.21
- COEP 0.57
- MACD
- CRIS -0.03
- COEP 0.30
- Stochastic Oscillator
- CRIS 38.78
- COEP 100.00
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.